Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma

Next Previous
Trial Profile

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Fludarabine; Lenalidomide; Prednisone; Rituximab; Vincristine
  • Indications B-cell lymphoma; Follicular lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ZUMA-22
  • Sponsors Kite Pharma

Most Recent Events

  • 09 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 04 Apr 2024 Planned End Date changed from 1 Jan 2031 to 1 Oct 2030.
  • 04 Apr 2024 Planned primary completion date changed from 1 Jan 2031 to 1 Oct 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top